What question did this study set out to answer?

This review aims to summarize evidence on pharmacologic and neuromodulatory interventions for reducing suicide risk across psychiatric disorders.

An Update on Somatic Treatments for Suicide Risk

View Full Paper

Ask AI

Bookmark

This review aims to summarize evidence on pharmacologic and neuromodulatory interventions for reducing suicide risk across psychiatric disorders.
Sourced evidence from randomized controlled trials, meta-analyses, national registry studies, and large cohort studies.
Examined associations between treatments and outcomes such as suicide deaths, attempts, and ideation.
Appraised studies based on design, sample size, population, and outcome definitions.
Lithium and clozapine were linked to reduced suicidal behavior in bipolar disorder and schizophrenia, respectively.
Intravenous ketamine produced rapid reductions in suicidal ideation, independent of antidepressant effects, but was transient.
Electroconvulsive therapy rapidly reduced suicidal ideation and mortality, with some observational studies showing lower suicide risk with opioid use disorder medications.

No takes yet. Share an insight, caveat, or question.

Scoping review summarizes pharmacologic and neuromodulatory effects on suicide risk across disorders, highlighting treatment implications.

Rizk et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Scoping review summarizes pharmacologic and neuromodulatory effects on suicide risk across disorders, highlighting treatment implications.